BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36463324)

  • 21. Metastasis and immunosuppression promoted by mtDNA and PD-L1 in extracellular vesicles are reversed by WGP β-glucan in oral squamous cell carcinoma.
    Ko HH; Peng HH; Cheng AN; Chou HE; Hou HH; Kuo WT; Liu WW; Kuo MY; Lee AY; Cheng SJ
    Cancer Sci; 2023 Oct; 114(10):3857-3872. PubMed ID: 37525561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein Kinase D3 Promotes the Reconstruction of OSCC Immune Escape Niche Via Regulating MHC-I and Immune Inhibit Molecules Expression.
    Lv D; Chen J; Kang Y; Luo M; Chen H; Cui B; Wang L; Wang J; Zhou X; Feng Y; Huang L; Zhang P
    J Immunother; 2021 Nov-Dec 01; 44(9):339-347. PubMed ID: 34545012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma.
    Monteiro de Oliveira Novaes JA; Hirz T; Guijarro I; Nilsson M; Pisegna MA; Poteete A; Barsoumian HB; Fradette JJ; Chen LN; Gibbons DL; Tian X; Wang J; Myers JN; McArthur MJ; Bell D; William WN; Heymach JV
    Cancer Prev Res (Phila); 2021 Mar; 14(3):313-324. PubMed ID: 33277316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes.
    Le Meitour Y; Foy JP; Guinand M; Michon L; Karabajakian A; Fayette J; Saintigny P; Mahtouk K
    Oral Oncol; 2024 Feb; 149():106680. PubMed ID: 38218022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Guanylate binding protein 5 triggers NF-κB activation to foster radioresistance, metastatic progression and PD-L1 expression in oral squamous cell carcinoma.
    Chiu HW; Lin CH; Lee HH; Lu HW; Lin YK; Lin YF; Lee HL
    Clin Immunol; 2024 Feb; 259():109892. PubMed ID: 38185269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-23 receptor defines T helper 1-like regulatory T cells in oral squamous cell carcinoma.
    Li W; An N; Wang M; Liu X; Mei Z
    Immun Inflamm Dis; 2022 Dec; 10(12):e746. PubMed ID: 36444617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
    Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
    Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
    Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
    Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms regulating PD-L1 expression on tumor and immune cells.
    Chen S; Crabill GA; Pritchard TS; McMiller TL; Wei P; Pardoll DM; Pan F; Topalian SL
    J Immunother Cancer; 2019 Nov; 7(1):305. PubMed ID: 31730010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinoma.
    Nieto C; Miller B; Alzofon N; Chimed T; Himes J; Joshi M; Gomez K; Chowdhury FN; Le PN; Weaver A; Somerset H; Morton JJ; Wang JH; Wang XJ; Gao D; Hansen K; Keysar SB; Jimeno A
    J Natl Cancer Inst; 2023 Nov; 115(11):1392-1403. PubMed ID: 37389416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
    Pang X; Wang SS; Zhang M; Jiang J; Fan HY; Wu JS; Wang HF; Liang XH; Tang YL
    Cancer Immunol Immunother; 2021 Apr; 70(4):1015-1029. PubMed ID: 33104837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fat mass and obesity-associated protein regulates arecoline-exposed oral cancer immune response through programmed cell death-ligand 1.
    Li X; Chen W; Gao Y; Song J; Gu Y; Zhang J; Cheng X; Ai Y
    Cancer Sci; 2022 Sep; 113(9):2962-2973. PubMed ID: 35289035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of PD-1/PD-L1 on immune microenvironment in oral leukoplakia and oral squamous cell carcinoma.
    Xu SB; Wang MY; Shi XZ; Wang Q; Yu M; Zhang W; Xu XH; Liu LK
    Oral Dis; 2023 Nov; 29(8):3268-3277. PubMed ID: 35921211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immuno-oncologic signature of malignant transformation in oral squamous cell carcinoma.
    Elnaggar M; Chaisuparat R; Ghita I; Bentzen SM; Dyalram D; Ord RA; Lubek JE; Younis RH
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2023 Nov; 136(5):612-622. PubMed ID: 37739913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors.
    Gao A; Pan X; Yang X; Lin Z
    Invest New Drugs; 2021 Aug; 39(4):1132-1138. PubMed ID: 33594603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside.
    Nocini R; Vianini M; Girolami I; Calabrese L; Scarpa A; Martini M; Morbini P; Marletta S; Brunelli M; Molteni G; Parwani A; Pantanowitz L; Eccher A
    Clin Exp Dent Res; 2022 Jun; 8(3):690-698. PubMed ID: 35593124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.
    Satgunaseelan L; Gupta R; Madore J; Chia N; Lum T; Palme CE; Boyer M; Scolyer RA; Clark JR
    Pathology; 2016 Oct; 48(6):574-80. PubMed ID: 27590194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of PD-1 and PD-L1 expression in oral leukoplakia and oral squamous cell carcinoma: an immunohistochemical study.
    Greeshma LR; Joseph AP; Sivakumar TT; Raghavan Pillai V; Vijayakumar G
    Sci Rep; 2023 Dec; 13(1):21698. PubMed ID: 38066025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma.
    Blatt S; Krüger M; Rump C; Zimmer S; Sagheb K; Künzel J
    PLoS One; 2022; 17(5):e0269136. PubMed ID: 35622885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.